The "Innovative AI-enabled Clinical Trial Companies: Strategic Profiling and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allowing patient-centric clinical trial modalities.
Clinical trials rely on large-scale longitudinal patient databases in the form of electronic medical records (EMRs). Despite the availability of robust databases, most lack clarity and structure, making them difficult to read. As a result, the rapid adoption of AI/machine learning (ML) algorithms and platforms allows easy structuring of unstructured databases, and the use of electronic health records (EHRs) represents a vast, rich, and highly relevant data source that holds tremendous potential to improve the global clinical trial landscape.
Incorporating integrated AI-driven solutions in clinical trial design, site selection, and patient identification and retention will ease the go-to-market strategy for various CROs and pharmaceutical companies. AI is gaining significance in clinical trials to reduce cost, increase efficiency, and support the transition to decentralized trials through remote patient recruitment, management, and engagement. Interactive platforms in the form of voice recognition, chatbots, and other devices ensure better patient adherence and greater retention. These platforms are also highly beneficial in the selection of appropriate investigators and trial sites. Randomized control trials (RCTs) represent another important area seeing increased AI application, where sponsors can leverage the technology to analyze the vast site-level datasets generated for greater visibility into trial design and implementation.
Leading CROs, such as Icon plc, Novotech, Syneos Health, and IQVIA, as well as several pharmaceutical companies, including BMS, have successfully deployed AI-based platforms to support site selection and patient recruitment. BMS, Amgen, AstraZeneca, and Novartis, among several other companies, are also applying AI in clinical trials to enable the optimization of different stages, with the intent of reducing overall trial timelines.
AI brings innovation fundamental to transform clinical trials, such as collecting and analyzing RWD, seamlessly combining phase I and II of clinical trials, and developing novel patient-centric endpoints. AI can also be leveraged to create standardized, structured, and digital data elements from a range of inputs. As AI-enabled study design helps optimize and accelerate the creation of patient-centric designs, it significantly reduces patient burden, increases the likelihood of success, decreases the number of amendments, and improves the overall efficiency of trials. Together, large technology providers and pharmaceutical start-ups are setting the stage for more effective clinical trials in the future.
Growth Opportunity Universe
- Data Interoperability with Federated Data Systems
- Data Restructuring and Distribution with LLMs for Patient Identification and Enrollment
- RWD/RWE-based Oncology Trial Design and Protocol Optimization
A selection of companies mentioned in this report includes
- Amgen
- AstraZeneca
- BMS
- ConcertAI
- Deep 6 AI
- Icon plc
- IQVIA
- Mendel Health
- Novartis
- Novotech
- Oncoshot
- Owkin
- Paradigm
- Phesi
- QuantHealth
- Syneos Health
- Unlearn
Key Topics Covered:
Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative
- The Impact of the Top 3 Strategic Imperatives on the AI-enabled Clinical Trials Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
Ecosystem
- Scope of Analysis
- Segmentation
- Drug Development Vendor Ecosystem
- AI Vendor Ecosystem
- Value Proposition of Using AI in Clinical Trials
- Strategic Profiles Based on Unique Value Proposition
Growth Opportunity Analysis
- Growth Drivers
- Growth Restraints
- Regulatory Scenario: AI Use in Clinical Trials
- ConcertAI: Company Overview
- ConcertAI: Value Proposition
- ConcertAI: Growth Strategy
- Unlearn: Company Overview
- Unlearn: Value Proposition
- Unlearn: Growth Strategy
- Phesi: Company Overview
- Phesi: Value Proposition
- Phesi: Growth Strategy
- QuantHealth: Company Overview
- QuantHealth: Value Proposition
- QuantHealth: Growth Strategy
- Owkin: Company Overview
- Owkin: Value Proposition
- Owkin: Growth Strategy
- Deep 6 AI: Company Overview
- Deep 6 AI: Value Proposition
- Deep 6 AI: Growth Strategy
- Paradigm: Company Overview
- Paradigm: Value Proposition
- Paradigm: Growth Strategy
- Mendel Health: Company Overview
- Mendel Health: Value Proposition
- Mendel Health: Growth Strategy
- Oncoshot: Company Overview
- Oncoshot: Value Proposition
- Oncoshot: Growth Strategy
- Amazon Web Services, Inc.
- AWS: Value Proposition
- AWS: Growth Strategy
List of Exhibits
For more information about this report visit https://www.researchandmarkets.com/r/1jwx1c
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808942960/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
